Background Previous reviews have evaluated economic analyses of lipid-lowering therapies using lipid levels as surrogate markers for cardiovascular disease. However, drug approval and health technology assessment agencies have stressed that surrogates should only be used in the absence of clinical endpoints. Objective The aim of this systematic review was to identify and summarise the methodologies, weaknesses and strengths of economic models based on atherosclerotic cardiovascular disease event rates. Methods Cost-effectiveness evaluations of lipid-lowering therapies using cardiovascular event rates in adults with hyperlipidaemia were sought in Medline, Embase, Medline In-Process, PubMed and NHS EED and conference proceedings. Search results were independently screened, extracted and quality checked by two reviewers. Results Searches until February 2016 retrieved 3443 records, from which 26 studies (29 publications) were selected. Twenty-two studies evaluated secondary prevention (four also assessed primary prevention), two considered only primary prevention and two included mixed primary and secondary prevention populations. Most studies (18) based treatment-effect estimates on single trials, although more recent evaluations deployed metaanalyses (5/10 over the last 10 years). Markov models (14 studies) were most commonly used and only one study employed discrete event simulation. Models varied particularly in terms of health states and treatment-effect duration. No studies used a systematic review to obtain utilities. Most studies took a healthcare perspective (21/26) and sourced resource use from key trials instead of local data. Overall, reporting quality was suboptimal. Conclusions This review reveals methodological changes over time, but reporting weaknesses remain, particularly with respect to transparency of model reporting.
Introduction
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability in the western world [1] . Numerous studies have demonstrated that reducing low-density lipoprotein cholesterol (LDL-C) levels, mainly via statin therapy, reduces the risk of ASCVD, with a strong direct relationship between LDL-C level and ASCVD events [2, 3] . Patients at very high ASCVD risk [2] may benefit from even greater reductions in LDL-C levels. The European Society for Cardiology/European Atherosclerosis Society (ESC/EAS) recommended this year that all patients at very high CV risk have an LDL-C goal of \70 mg/dL (1.8 mmol/L) or C50% LDL-C if the baseline is between 1.8 and 3.5 mmol/L (70 and 135 mg/ dL) [4] . This follows guidance by the Third Joint Task Force of European and Other Societies on Cardiovascular Disease (CVD) Prevention in Clinical Practice in 2003 which recommended an LDL-C level of \100 mg/dL as the goal of therapy for patients at high risk for coronary heart disease (CHD) [5] . Earlier guidelines from the US (National Cholesterol Education Program-Adult Treatment Panel III [NCEP-ATPIII]) also provided target LDL-C goals for specific patient groups. However, in recent guidelines from the American College of Cardiology and the American Heart Association (ACC/AHA), recommendations do not identify specific lipid level targets, but advocate different intensities of treatment depending on patients' level of CV risk [5] .
Despite the evidence linking lipid-level lowering with subsequent reductions in CV risk, such lipid outcomes are still only surrogate markers for clinical disease outcomes. Health technology assessment agencies have emphasised the need to use clinical endpoints that reflect how a patient feels rather than surrogate endpoints (such as the laboratory tests and imaging findings) [6] .
Cost-effectiveness analyses (CEAs) using decision analytic models (DAMs) are widely used in many countries to evaluate lipid-lowering therapies and make reimbursement decisions. However, many previous CEAs of lipidlowering therapies have only included surrogate outcomes such as LDL-C levels [7, 8] . A recently published systematic review of CEAs has also highlighted potential issues with the reporting of such CEAs and has suggested that although reporting standards are reasonably good, there is still room for improvement [9] . In addition, although results based on DAMs are useful for decision making, modellers face many decisions with respect to the structure and evidence sources used when constructing de novo models. It is therefore important that modellers are aware of all possible approaches and make explicit the potential implications and limitations of the choices they make. Therefore, there is a need for systematic reviews summarising the modelling approaches that have been used previously, and particularly how these have changed over time in order to select the most appropriate approach. In particular, our review focuses only on CEAs using hard endpoints (i.e. myocardial infarction [MI] , stroke and other ASCVD outcomes) from clinical trials, as opposed to surrogate endpoints such as the change in LDL-C level. The aim is to provide future investigators with an overview of how cost-effectiveness models of lipid-lowering therapies have developed alongside the evidence base used to inform them.
Methodology
To reduce the risk of bias and error, this systematic review adhered to a pre-specified protocol and 'gold standard' methodologies recommended by the Cochrane Collaboration [10] and the Centre for Reviews and Dissemination (York, UK) [11] . The Preferred Reporting System for Systematic Reviews and Meta-Analysis (PRISMA) strategy was followed [12] .
The review included CEAs that used ASCVD event rates to report on the cost effectiveness of lipid-lowering therapies used for the treatment of elevated lipid levels in adults (C18 years) with primary hyperlipidaemia (including familial and non-familial). Studies in patients with organ transplantations, infectious diseases, significant heart failure (New York Heart Association [NYHA] grade III-IV) or significant renal dysfunction (Stage 4-5) were excluded as these were considered to be major confounding comorbidities. Eligible lipid-lowering therapies included monotherapies and combination therapies that were licensed for use in Europe or the US including statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, cholesterol absorption inhibitors, nicotinic acids, bile acid resins, fibrates, and cholesteryl ester transfer proteins. Study inclusion was not limited by language, date or publication status, but studies had to report quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs) or the probability of being cost effective at a given threshold (as reported by the study authors). Studies that only used surrogates to inform the treatment effect (e.g. lipid levels) were excluded.
Extensive literature searches were performed using search strategies developed by an Information Specialist (full search strategies are available in Online Resource 1, see electronic supplementary material [ESM] [2013] [2014] [2015] . The reference lists of included studies and systematic reviews were checked for further studies. Identified references were downloaded in Endnote X6 software (Thomson Reuters, New York, USA) for further assessment and handling, and duplicate records were removed.
The study selection process was performed by CW, SR and SD working independently. Data were extracted into a specifically developed spreadsheet in Excel 2010 (Microsoft Corporation, Redmond, Washington, USA). One reviewer extracted the study data and a second reviewer independently reviewed the data against the original paper for completeness and accuracy. Data were extracted on the study design, modelling methods, data inputs and sources, model assumptions, patient populations, and ASCVD outcomes.
The methodological quality of each study was assessed using the criteria of using the Drummond checklist for economic evaluations [13] . The quality assessments were performed independently by CW, SR and SD. Any discrepancies between reviewers during data extraction or quality assessments were resolved through consensus or consultation with NA.
The key features of the economic evaluations are discussed and summarized with respect to their methodologies, including the similarities and differences between studies over time. Studies are classified according to population type into three categories: secondary prevention (i.e. in patients who have already experienced a cardiovascular event), high-risk primary prevention (i.e. in patients who have not yet experienced a cardiovascular event, but are at high risk of an event due to other risk factors or comorbidities) and primary prevention (i.e. in samples selected from the general population that were not selected on the basis of previous events or risk factors). The weaknesses and strengths of the evaluations are discussed, in addition to the consequent implications for reliability of the evidence base as a whole. Suggestions for improvements in future research and economic evaluations are identified.
Results
Literature searches up to February 2016 retrieved a total of 3443 titles and abstracts (after de-duplication). After screening, a total of 88 references were selected as full papers for further assessment. After subsequent detailed review, 26 papers were selected as meeting all of the inclusion criteria. Five systematic reviews were also checked for references and led to retrieval of a further three papers. In total, 26 unique studies (reported in 29 papers) were included in the review. Scuffham and Chaplin [14] , Chaplin et al. [15] and Scuffham and Kosa [16] used the same model structure, compared the same treatments in the same population and used the same effectiveness source and so were considered as the same study applied in three different countries: the UK, the Netherlands and Hungary. This was the same for Caro et al. [17] and Caro et al. [18] , which applied the analysis to the UK and four other countries (Canada, Sweden, Belgium and South Africa).
A summary of the searching, screening and inclusion assessment process in accordance with the PRISMA checklist is presented in Fig. 1 [12] .
Year and Country
The included studies were published over a time span of approximately 20 years; the earliest publications by Jonsson et al. [19] and Pharoah and Hollingworth [20] were published in 1996 and the most recent publication was by Ribeiro et al. [21] in 2015. The year of publication reflects both the treatment of interest and the trial used to source its effectiveness, as discussed below. The two countries which were most studied were the UK and the US (six each). In terms of population, most of the primary prevention studies (five out of six studies) were from a UK perspective; the remaining study was set in Brazil [21] .
Populations/Treatments/Effectiveness Sources
One study in the Netherlands [22] did not define populations according to primary or secondary prevention, but according to CVD risk level. It compared statin with no statin, using data on effectiveness from trials deemed to reflect the particular CVD risk level. In fact, these trials were conducted either in primary prevention populations, such as the West of Scotland Coronary Prevention Study (WOSCOPS) [23] and the Air Force Coronary Atherosclerosis Prevention Study (AFCAPS) [24] , or secondary populations, such as the Scandinavian Simvastatin Survival Study (4S) [25] , the Cholesterol and Recurrent Events (CARE) study [26] and the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial [27] .
One US study [28] mismatched the data to estimate effectiveness for a population described as primary prevention with a data source which was a secondary prevention study (the Veteran Affairs Cooperative Studies Program HDL-C Intervention Trial [VA-HIT]) [29] .
Primary Prevention
Six studies, reported in seven papers, conducted CEAs in a primary prevention population (details of patient CVD history for each study are available in Online Resource 2, see ESM) [17, 18, 20, 21, [30] [31] [32] . Four of these studies also analysed a secondary prevention population [20, 21, 31, 32] . No two populations were identical with, for example, Pharoah and Hollingworth [20] including only men with unspecified CVD risk in the UK and Ribeiro et al. [17, 18, 20] . Pharoah and Hollingworth [20] estimated effectiveness from WOSCOPS [23] . Pickin et al. [31] used effectiveness data from either the WOSCOPS [23] or, depending on CHD risk, the 4S study [25] . Caro et al. [17, 18] analysed the WOSCOPS study to compare pravastatin to no statin. Nherera et al. [30] used a meta-analysis to estimate effectiveness when comparing atorvastatin with simvastatin. Finally, Ribeiro et al. [21] in Brazil and Ward et al. [32] in the UK both used a meta-analysis to compare statin with no statin and high, intermediate and low dose with no statin, respectively.
Secondary Prevention
Twenty-two studies reported in 24 papers analysed a secondary prevention population (details of patient CVD history for each study are available in Online Resource 2, see ESM) [14-16, 19, 33-48] . The precise population varied. One study only described the population of interest as secondary prevention, with no further details [47] . Two studies analysed those with a history of any CVD, including CHD, but also stroke/transient ischaemic attack (TIA) [21, 32] . One study analysed those described as being at high risk, which included both those with a history of CVD or diabetes mellitus [33] . Four studies analysed those with a history of CHD only [20, 37, 42, 45] . Four other studies were in a similar population, referred to as MI or stable angina [19, 38, 39, 44] . Two further studies were in narrower sub-populations of those with a history of MI only, one with no age limit [46] and one in those aged at least 75 years [36] . Another was in those with CHD, but with low high-density lipoprotein cholesterol (HDL-C) and LDL-C levels [43] .
The earliest comparison was simvastatin versus no statin (six studies). These were some of the earliest CEAs, and all were reported in the 1990s. All six were based on the 4S trial [25] . Four were in populations defined as angina/MI studies, three of which were applied to Scandinavia and the fourth was applied to Canada [44] . One other study [20] applied the results of the 4S trial to the UK in a wider CHD population. Pickin et al. [31] also applied the 4S study results to a CHD population in the UK, but one specifically labelled as having an annual CHD risk of 4.5%.
Between 1998 and 2002, focus turned to the comparison of pravastatin versus no statin (six studies). All except one of these studies were in populations labelled as CHD and four used effectiveness data from the CARE study [26] , applied first to Germany [45] , then the US [36, 46] , and finally in Hong Kong [35] . Muls et al. [42] applied effectiveness data from the Pravastatin Limitation of Atherosclerosis in the Coronary arteries (PLAC I) [49] and (PLAC II) [50] studies to Belgium and the US, and Glasziou et al. [37] applied effectiveness data from the LIPID trial [27] to Australia.
Gemfibrozil was compared with no statin in only one study [43] , which analysed the VA-HIT [29] , conducted in those with CHD, but also low HDL-C and low LDL-C levels in the US.
In 2004, two of three papers reported a study comparing fluvastatin with no statin (labelled as dietary counselling only), applying the Lescol Intervention Prevention Study (LIPS) [51] effectiveness data to the UK and the Netherlands [14, 15] and, in a subsequent paper published in 2006, applying results to Hungary [16] .
Atorvastatin was compared with either simvastatin, gemifibrozil, pravastatin or no statin in a total of six studies. In 2007, atorvastatin was compared with simvastatin [34] using a meta-analysis in the US in two different populations, namely those with a history of acute coronary syndrome (ACS) and those with stable CHD. This comparison was also studied in Canada [48] , following earlier work in Scandinavia [52] , analysing the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial [3] in those who have had an MI. Atorvastatin was also compared with no statin in CHD based on the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial [53] in the US [41] . It was also compared with no statin, but in those with a history of stroke or TIA, applying the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial [54] data to the US. Atorvastatin and simvastatin were both compared with no statin, based on a meta-analysis, in Brazil in a population defined as high risk (CVD or diabetes mellitus) [33] .
Three of the above-mentioned statins, simvastatin, pravastatin and atorvastatin, were compared with gemfibrozil [47] in the Philippines in a population described solely by the term 'secondary prevention'. The study used separate trials for each of the treatments, the MRC/BHF (Medical Research Council/British Heart Foundation) Heart Protection Study [55] for simvastatin, the GREek Atorvastatin and Coronary-heart disease Evaluation (GREACE) study [56] and the LIPID study [27] for pravastatin and the VA-HIT study [29] for gemfibrozil.
Finally, two studies compared statin with no statin, both based on a meta-analysis and both in a CVD population, one in the UK [32] and the other, the most recent CEA, in Brazil [21] .
Model Structure/Modelling Technique
Markov models or life table/survival analysis were the most common analytic techniques. Most studies (14 out of 26) used Markov models, especially the latest studies (eight out of the ten most contemporary studies since 2005). Most studies also chose a 'lifetime' time horizon, running the model until all simulated patients had died to capture all possible costs and patient outcomes associated with the target intervention (15 studies). Other studies used a horizon of 5-10 years [14-18, 33, 41, 42] . Scuffham et al. [14] [15] [16] considered a 10-year horizon to be reasonable given that the population have coronary artery disease (CAD) and a shorter life expectancy. Both Scuffham et al. [14] [15] [16] and Caro et al. [17, 18] also cited the trial duration as a reason. The others did not provide specific reasons. The full range of time horizons is summarised in Table 1 .
Reported cycle length was either annual (seven studies) or monthly (two studies). Only two of the nine studies reporting cycle length used monthly cycles [14] [15] [16] [17] [18] . Only Scuffham et al. [14] [15] [16] justified cycle length, by it being based on other economic evaluations of statins. None of the Markov cohort models explicitly reported incorporation of tunnel states and no model stated that transition probabilities varied with history of events. However, further correspondence with the authors of the model based on IDEAL [3] suggested that in fact the model did use tunnel states [52] .
Four of the 12 non-Markov modelling studies reported use of a lifetable method in their economic evaluation [20, 22, 31, 44] and a further three studies reported use of survival analysis [19, 37, 39] . Although the details varied, these methods basically involve plotting the proportion of a cohort still alive at regular time intervals and then estimating life expectancy as the area under the curve. Only two studies explicitly reported counting events other than death. van Hout and Simoons [22] calculated the probabilities of stroke, MI, percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass graft (CABG) and Rivière et al. [44] reported that survival curves were fitted for MI, CABG, PTCA, stroke and TIA.
Kongnakorn et al. [40] was the only study that employed a discrete-event simulation (DES) model in which an individual patient was generated and assigned specific characteristics (such as age, sex, medical history, prior TIA or stroke, etc.). DES models differ from Markov models in that time to event (e.g. time to occurrence of an MI) is simulated instead of the transition probability of the event in a fixed period of time (the cycle); for example, from the health state 'healthy' to the health state 'post MI'.
The remaining four studies [28, 35, 41, 45] appeared to have used a more simplistic or less clear approach. Mullins et al. [41] was the only study to measure effectiveness only as CV events avoided. Because of this, a method for estimating life expectancy, such as a Markov model or life table, was not required. Chau et al. [35] and Szucs et al. [45] both seemed to use events avoided taken from the CARE trial [26] Only the Markov and DES models are discussed in the following sections on model structure. This is because these types of models are generally perceived to be the current standard and therefore a discussion of the details of structure most useful. Also, as already mentioned, the other main modelling approach (i.e. lifetable/survival analysis) is generally quite simple in that it mostly involves only one event (death) and thus only two health states (alive and dead).
Health States
Studies based on Markov models varied with respect to health states and process. The health states modelled (including dead) are shown in Table 1 . Depending on type of target population (primary or secondary prevention), patients started in the 'healthy (no event or event-free)' or 'CHD no events (or healthy after index percutaneous coronary intervention [PCI])' state. Then, during each annual or monthly cycle of the model, the cohort was allocated across several health states including MI, stroke, angina, revascularisation (CABG/PTCA/PCI) and dead. Death (transition to the dead state) was often subdivided into cardiac death or death due to other reason. MI/post-MI and stroke/post-stroke were the most frequent health states. In addition, some studies subdivided 'angina' into 'stable' or 'unstable' angina [21, 32, 46] . Nherera et al. [30] was the only model involving 'heart failure' and 'peripheral artery disease (PAD)' states, whereas, the Ward et al. [32] model was the only one to have a TIA state.
Ribeiro et al. [21] and Ward et al. [32] both had separate Markov models for primary and secondary prevention. Muls et al. [42] used the simplest model (post-MI or dead), with patients only entering after a non-fatal MI event. The effect of pravastatin was estimated partly based on this model and directly from the difference in risk of fatal and non-fatal MIs from the PLAC studies [49, 50] . Tsevat et al. [46] compared two different Markov models, one a 'mortality model' and one a 'recurrent events' model, with the use of different assumptions regarding the long-term benefit of therapy. The recurrent events models estimated the transitions between no event, non-fatal event (MI, CABG/ PTCA, stroke, unstable angina) and the dead state. Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering TherapiesNyman et al. [43] reported use of the same structure as Johannesson et al. [38] and modelled four health states: CHD no event, post-coronary event (year 1), post-coronary event (subsequent years) and dead. Caro et al. [17, 18] used a two-state (mortality) model with only transition from healthy to dead with nine combinations of cardiovascular cause. In the Chan et al. [34] study, there were two different secondary prevention populations, ACS (those immediately following an ACS event) and stable angina. This was modelled by having patients in the ACS cohort start out in a separate Markov model for the first 2 years and then transition into the stable CAD Markov model. Patients were at risk annually of MI, stroke, re-hospitalization, revascularization and death.
Scuffham et al. [14] [15] [16] , in three separate papers, applied the same modelling structure: patients following successful PCI entered the state 'healthy after index PCI' and then could transition to one of the following: postacute myocardial infarction (AMI), post-CABG, post-PCI (subsequent to the index one) or dead (due to cardiac or other cause).
The only DES study modelled the patient according to their characteristics, in terms of events and treatments experienced during the simulation [40] . Each patient was exposed to one of the following events at a time: stroke, MI, TIA, unstable angina, revascularization, cardiac death, and death due to other causes.
Baseline Cardiovascular Disease Risk
Each Markov study employed a range of sources for the transition probabilities that represent the underlying risk of ASCVD, including published literature, the Framingham [57] risk equation, registered databases and author assumptions.
Seven of the fourteen Markov model studies [14-18, 33, 38, 43, 46, 48] modelled transition probabilities based on the same trial data from which the treatment effect was estimated. Five of these studies only used the trial data for the whole time horizon. In contrast, Muls et al. [42] used the PLAC studies to estimate the risk of initial events and Framingham [57] data were used to project the risk of mortality 10 years post-MI. Tsevat et al. [46] used CARE trial data in the recurrent events model but extrapolated beyond the trial using US life tables for other-cause mortality and the Coronary Heart Disease Policy Model (CHDPM) for CHD mortality rate in the mortality model.
Chan et al. [34] performed a pooled analysis of clinical end points from the four clinical trials divided into two categories: PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy trial) [58] and A to Z trial [59] for ACS and TNT (Treating to New Targets study) [60] , and IDEAL [3] 
Ribeiro et al. [21] and Nherera et al. [30] took baseline risks from the NICE Technology Appraisal TA 94 [61] . Nherera et al. also adjusted those values for the familial hypercholesterolaemia (FH) population by using the ageadjusted RR of CVD reported from the Simon Broome Register, which is a cohort of people with FH [30] . Ganz et al. [36] used all-cause mortality rates from vital statistics data, and other transition probabilities were taken from a variety of observational studies. In the Ward et al. model [32] , UK-specific incidence rates were taken from multiple sources including the Bromley Coronary Heart Disease Register (BCHDR) [62] , Oxfordshire Community Stroke Project [63, 64] , Nottingham Heart Attack Register (NHAR) [65] , South London Stroke Register (SLSR) [66] and a trial [67] . It was not clear what data TumananMendoza and Mendoza [47] used. The only DES study [40] also used trial data [54] .
Type of Treatment Effect
A summary of how treatment effects (e.g. statin versus no statin) were incorporated in each model is provided in Table 1 . The most frequently encountered measure of treatment effect from the contemporary literature was RR. Six [21, 30, [32] [33] [34] 48] of the studies used RRs to measure treatment effect. It is noted that RRs of death estimated separately for different causes were used in four studies [14, 15, 32, 33, 48] . Three studies [14] [15] [16] [17] [18] 46 ] used separate event rates per treatment. Three studies [36, 38, 43] used a risk difference (RD) approach. The only DES study [40] used a hazard ratio (HR). In the remaining two studies [42, 47] , it was unclear what methodology was used. Muls et al. [42] reported a difference in number per 1000 of nonfatal MIs, although it was unclear how this was estimated or what the treatment effect on mortality was. TumananMendoza and Mendoza [47] provided no estimate of treatment effect.
Duration of Treatment Effect
The treatment effect over time was modelled using various assumptions in the Markov models. Four studies [21, 30, 32, 34] extrapolated the treatment effect at a constant value for the whole lifetime time horizon. Chan et al. [34] assumed this in the base case (i.e. a constant risk reduction as observed during trial follow-up) but conducted sensitivity analyses for the period after 5 years as a 50% decrement in risk reduction and no further risk reduction (RR = 1).
Four studies [38, 43, 46 , 48] using a lifetime time horizon assumed the treatment effect over time declined in the sense that there was no treatment effect after a fixed period. This period was 5 years for Johannesson et al. [38] , Nyman et al. [43] and Wagner et al. [48] . Tsevat et al. [46] assumed that the treatment effect lasted the whole lifetime, but only using their mortality model. In the recurrent events model, effect was assumed to last for only 10 years, although the effect of changing this was tested in a sensitivity analysis. The Scuffham et al. model [14] [15] [16] assumed no decrease in the treatment effect, but the time horizon was only 10 years. Araújo et al. [33] also assumed no decrease in the treatment effect over the full time horizon, but this was only 5 years. Muls et al. [42] assumed the treatment effect, as observed in the PLAC trial [49, 50] , applied during the 10-year time horizon only to years 2 and 3. Two studies failed to explicitly report this information [36, 47] . The only DES study also applied a constant treatment effect over a lifetime [40] . Of 14 Markov model studies reviewed, very few modelled the impact of long-term compliance. Ward et al. [32] suggested as much, but then concluded that ''sensitivity analysis on compliance and continuance assumptions shows that the impact on cost-effectiveness results is not likely to be significant.'' Ribeiro et al. [21] have suggested that use of compliance data from trials may lead to overestimates of cost effectiveness because real-world compliance is often lower than that found in trial situations. Caro et al. [17, 18] also commented that randomized trial results do not reflect clinical practice. Nherera et al. [30] assumed that compliance rates were the same for all statins and that there were no significant differences in side effects.
Utilities
Twelve out of 26 studies conducted cost-utility analyses (CUAs), thus requiring utility values (See Table 2 ). Such studies have become more common with seven out of ten studies (2005-2015) applying this method. An earlier study [43] conducted a CUA as a sensitivity analysis. Utility type (indirect, e.g. EQ-5D or direct, e.g. time trade-off [TTO]) was not reported or was unclear from the references in the majority (nine of 12) studies. The only studies which reported sources with established methods for estimation were Nyman et al. [43] and Ganz et al. [36] , which used TTO, and Ward et al. [32] , which used EQ-5D. Also, none of the studies used a systematic review in order to obtain utilities: nine out of 12 used a focused literature review and the rest used a single study. The most common (10 out of 12) utility model has been classified as 'absolute' in the sense that a utility between 0 and 1 was used to weight time in state for each of the CVD states (e.g. MI). This contrasts with an 'additive' model in which a decrement is used; that is, subtracted to estimate the effect of a CVD event. The only two studies that did not use an absolute utility model, at least solely, were Chan et al. [34] and Scuffham et al. [14] [15] [16] , which both used absolute utility values for chronic health states such as post-MI. They then subtracted a disutility for acute events such as 'acute MI' or revascularisation. These disutilties were applied for a period longer than the cycle length (i.e. 2.5 months post-revascularisation or 2 months post-MI in Scuffham and Kosa [16] and Scuffham and Chaplin [14] , but for only 1 month post-CABG and 1 week post-PCI or post-ACS in Chan et al. [34] ). None of the models used a 'multiplicative' approach. In this approach, the effect of multiple events on the utility of an existing health state is mediated by multiplying the utility of the health state by a factor between 0 and 1 that is associated with each event.
Only one study in primary prevention only [30] conducted a CUA and thus estimated utilities, which came from various sources, including one of the other CUAs [34] . Two studies involved a CUA of both primary and secondary prevention, both of which used absolute utilities from various sources [21, 32] . Ribeiro et al. [21] sourced one value for stroke from Ward et al. [32] indirectly, in that they multiplied the value for MI with 0.8, which was the ratio of the two values in the Ward et al. study.
Two of the studies used single trials as sources for the utilities used in the models. Both of the trials provided measures of effectiveness. Tsevat et al. [46] used the CARE trial [26] and Glasziou et al. [37] used the LIPID trial [27] . The other four studies that used a single source, whilst appearing to be selective, were at least to some extent specific to the population; for example, Stahl et al. [68] in a stroke population for Kongnakorn et al. [40] , and Lindgren et al. [69] in a Swedish coronary care population for Wagner et al. [48] .
Costs/Resource Use
As shown in Table 3 , only five studies took a societal perspective and thus included indirect costs, one from the US [28] , one from Sweden [38] , one from Canada [48] , one from Hong Kong [35] and one from the Philippines [47] . Three other US studies [34, 36, 46] stated that they used a societal perspective, but there was no evidence that indirect (due to lost productivity) costs were included [13] .
For healthcare costs, every study used local prices (e.g. British National Formulary (BNF) in UK studies [20, 31] ), but these were combined with resource data from a variety of sources. The most common source, in ten studies, was the trial from which the effectiveness data were taken. These were WOSCOPS [23] in Caro et al. [17, 18] ; LIPID [27] in Glasziou et al. [37] ; 4S [25] in Johanneson et al. [38] , Jonsson et al. [19] and Jonsson et al. [39] ; SPARCL [54] in Kongnakorn et al. [40] ; PLAC I [49] and PLAC II [50] in Muls et al. [42] ; VA-HIT [29] in Nyman et al. [43] ; CARE [26] in Tsevat et al. [46] and IDEAL [3] in Wagner et al. [48] .
Study Quality
Overall, there appears to have been little improvement in transparency of reporting over time as evidenced by assessment using the Drummond checklist [13] . The results are provided in Table 4 and detailed criteria in Online Resource 3 (see ESM). Summary rating refers to the percentage of the Drummond criteria with a favourable response in relation to the number of questions appropriate to that study. Wagner et al. [48] and Kongnakorn et al. [40] scored favourably on 91% of the Drummond criteria that were eligible for that study type and seem to be well performed studies.
Discussion
To the best of our knowledge, this is the first systematic review of economic evaluations of lipid-lowering therapies that have modelled effectiveness informed by direct estimates of ASCVD events, as opposed to surrogates such as changes in lipid levels (e.g. LDL-C). Models based on LDL-C levels assume that the effect of the treatment on ASCVD risk is mediated only via changes in LDL-C levels, which may not necessarily be the case. Based on extensive literature searches, our review provides a Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapiescomprehensive and up-to-date assessment of the key methodological features of the current economic evaluations of lipid-lowering therapies based on actual clinical events. This can then be used to provide a basis for suggesting improvements in current practice and methodologies. The 26 studies included in our review were published over a wide time span of 20 years from Pharoah and Hollingworth [20] and Jonsson et al. [19] in 1996 to Ribeiro et al. in 2015 [21] . They included two primary prevention studies and 18 secondary prevention studies with an additional four that analysed both populations. One further study did not subdivide by prevention type, but instead by risk of CVD [22] . One further study mismatched the data to estimate effectiveness for a population described as primary prevention with a data source which was a secondary prevention study [28] . Over that 20-year period, several aspects of economic modelling have changed, treatments and the sources of their effectiveness being the main example. Early studies evaluated simvastatin mainly using 4S trial data [20, 31, 44] , followed by pravastatin, mostly from the CARE study [35, 36, 45, 46] , then gemfibrozil from the VA-HIT [43] , all versus no statin treatment. Later, atorvastatin was evaluated against simvastatin, using either the IDEAL trial [48] or meta-analysis [33, 34] . Two studies used a generic approach of comparing statin with no statin in a secondary prevention population [21, 32] and one study defined the population by risk as opposed to primary or secondary prevention [22] .
There has also been a trend towards Markov models and away from earlier approaches using life tables and more simplistic methods of extrapolation from trial data. Indeed, eight of the ten CEAs published over the period [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] were Markov models. In the Markov models, baseline risks to inform the transition probabilities were generally informed by data from the trials or meta-analyses from which the treatment effect was estimated. The same is also true of the only DES study [40] . What does not seem to [21] . Perhaps more importantly is that no studies adjusted transition probabilities for history (e.g. number of MIs or strokes that had occurred). Also, there was much variation in the type of health states, with only Ribeiro et al. [21] having included a stable angina state and only Nherera et al. [30] having included heart failure. In the 14 Markov models, baseline risk was estimated variously with half of the studies using the same trial data as for the treatment effect, although one study [42] extrapolated beyond the trial using Framingham data [57] . The other half used a variety of observational studies. How to apply the treatment effect also varied, the most common (six out of 14) being by use of an RR, but only four studies reported separated estimates for mortality of different causes. One study did not provide any estimate of treatment effect [47] . The majority of the Markov studies included in the review used a lifetime model with annual cycle length, but how to model the duration of the treatment effect was also very variable. Most studies assumed the same effect of treatment for a lifetime. For example, Ribeiro et al. [21] applied the value observed in the trial for a lifetime, although several studies [38, 43, 46, 48] assumed there was no treatment effect after a fixed period (e.g. 5 years) and one study [42] assumed there was no treatment effect for the first year.
For one of the other major modelling decisions, CUA has become the most common method of analysis. Unfortunately, systematic review methods have never been applied to source utilities and many studies have not reported the type of utility. The preference-based instrument used to collect utility was also poorly reported. Indeed, Ward et al. [32] is the most recent study to explicitly report using an accepted type, which was based on EQ-5D. Most studies used only absolute utility values, one per health state. Only two of the studies, both of which used a monthly cycle length, reported explicit adjustment for the period immediately following an acute ACS event or revascularisation. Both applied a utility decrement. However, this period was over multiple cycles in Scuffham and Chaplin, 2004 [14] , and Scuffham and Kosa, 2006 [16] and only one cycle or less in Chan et al. [34] .
In terms of the other major modelling decision, very few studies (five out of 26) have taken a societal perspective. This is not surprising given that a healthcare perspective is generally what is required for most reimbursement decisions, such as in the UK by NICE [70] . Most studies have sourced resources from the key trials as opposed to local data.
In the process of our systematic review, five previously published systematic reviews of CEAs of lipid-lowering therapies were found, published from 2007 until 2013 [9, [71] [72] [73] [74] . None of these reviews were limited to studies that used only direct ASCVD event rates (as opposed to surrogates) to estimate the treatment effect. In addition, two of the reviews failed to raise this as an important issue [72, 73] . In agreement with the findings of our review, one of the earlier systematic reviews published in 2007 [74] did state that the quality of reporting in CEAs was generally poor, although the authors noted reporting generally improved over time. A more recent review published in 2012 [9] also noted that further improvements are required. Our review shows that this is still the case and, to the best of our knowledge, our systematic review reports the most current CEAs of lipid-lowering therapy that use only direct ASCVD evidence.
Limitations of the Review
This review is somewhat limited by the quality of the reporting within the included studies. In some cases, this was less than optimal and so, where no clear information was available, we have had to record the data as not reported or unclear. In some cases, during the study selection process it was not always clear whether the study met the criteria for inclusion in the review. This was particularly the case with respect to the inclusion of patients with hyperlipidaemia. It may also be the case that older relevant studies may have been missed during the literature searching process due to poor indexing. Improvements in the indexing of economic studies over time have aided in the retrieval of more recently published economic studies. However, this risk is minimised by the checking of references lists from included studies and from other previously published reviews.
In addition, this review does not report the numerical results (i.e. costs, QALYs or ICERs). However, this is not the purpose of this review, which is about the methodology and the parameter sources in each model. Furthermore, the comparability and transferability of clinical and economic data are always lacking in economic evaluations [75] . Indeed, the studies cover a wide time span of 20 years from Pharoah and Hollingworth [20] and Jonsson et al. [19] in 1996 to Ribeiro et al. in 2015 [21] and, as is clear from the review, vary in many ways.
Conclusions
This systematic review of cost-effectiveness analyses of lipid-lowering therapies based on ASCVD event rates reveals that, although changes in methodologies have occurred over time, weaknesses still exist in model structures and the data sources on which models are based. More recent evaluations use Markov models, but there still remains great variability with respect to the structure of models and the sources used for model parameters; particularly with respect to the duration of the treatment effect and description of the health states/events used. Justification for the choice of parameters, including cycle length, is often lacking. No studies used a systematic review to obtain utilities; however, a limited number of studies used systematic reviews to inform clinical effectiveness inputs. Overall, we recommend improvements in the consistency and reporting of economic modelling of lipid-lowering therapies.
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